It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
On March 13, 2017, US District Judge Vince Chhabria ruled — over Monsanto’s objections — that certain documents obtained by plaintiffs through discovery could be unsealed. These documents are being collectively referred to as The Monsanto Papers. Following the unsealing of the first wave of documents in March 2017, the headlines began flooding in. Evidence was shown, via email exchanges and documents, that Monsanto ghostwrote studies on Roundup® for the Environmental Protection Agency (EPA). In addition, these documents contained evidence that Jess Rowland, former deputy division director at the EPA who chaired the agency's Cancer Assessment Review Committee (CARC), had an unusually close relationship with Monsanto. Under his watch in 2016, the CARC determined that glyphosate was "not likely to be carcinogenic to humans,” a conclusion that vastly differed from what the available research pointed to and what IARC concluded a year prior.
The latest round of Monsanto Papers has now been released to the public. Shortly after, Forbes was forced to pull a popular piece titled On GMO Regulation, USDA Hits ‘The Cluelessness Trifecta’ due to the uncovered deep collusion between Monsanto and the article’s author Henry Miller. Did this longtime media mouthpiece for Monsanto and its products offer up his position and name to be used as a propaganda arm by the company? An email exchange between Monsanto executives states: “Henry agreed to author an article on forbes.com. John will work with a team internally (within Monsanto) to provide a draft and Henry will edit/add to make it his own.”
Prior to being a contributor at Forbes and many other media outlets, Miller served for 15 years at the US Food and Drug Administration (FDA), holding a number of appointments, including that of the medical reviewer for the first genetically engineered drug evaluated by the FDA and the founding director of the FDA's Office of Biotechnology. Miller’s unethical tendencies as a media writer now call into question the credibility of his previous work within the US regulatory framework.